Nektar Therapeutics Liquidation Value

NKTR presents a modestly positive liquidation posture at March 31, 2026, driven almost entirely by its liquid asset base. Total assets of $763.3M consist predominantly of cash and investments: cash and cash equivalents of $149.6M (100% recovery), current AFS debt securities of $419.0M (effectively 100% at fair value, with only $1.0M net unrealized loss on a $695.2M amortized cost base), and noncurrent AFS debt securities of $162.9M (similarly near-par). The company's stated total cash and investments of approximately $731.6M is the dominant recoverable asset stack. PP&E is de minimis at effectively zero separate disclosure in XBRL — filing does not separately tag PP&E in TAG_CONTEXT, consistent with the asset-light, outsourced manufacturing model post-sale of the manufacturing facility to Gannet BioChem. Intangibles and goodwill carry zero recovery value. Other current assets of $20.4M and other noncurrent assets of $11.2M would be subject to haircuts and are largely immaterial relative to the liquid base.

On the liability side, face-value obligations are material. Total liabilities of $187.1M include: operating lease liabilities of $22.5M current and $60.6M noncurrent — a combined $83.1M — representing the Mission Bay and Third St. San Francisco facilities which management acknowledges are difficult to sublease in a weak life sciences market. This lease obligation does not extinguish on windup and must be settled at face. Accounts payable of $10.0M, accrued liabilities of $25.2M, and employee-related liabilities of $5.0M are face-value current obligations. Other noncurrent liabilities of $8.4M and restructuring-related contract termination costs (discussed in MD&A as ongoing, with $4.9M recognized in full-year 2025) add further tail liability. No debt instruments are present. Litigation reserve is explicitly tagged at zero, though two active lawsuits (Nektar v. Lilly, trial set September 2026; Schramke securities class action filed March 2026) represent unquantified contingent liabilities not reflected on the balance sheet.

Liquidation math: adjusted liquid assets of approximately $731M in cash and investments plus modest other current assets, against $187M in face liabilities (dominated by operating leases at $83M). Gross spread is strongly positive — estimated liquidation surplus to equity of approximately $540–580M before any haircuts on non-cash current assets and before contingent litigation exposure. This compares to reported stockholders' equity of $576.2M. The MFFAIS CLV/LLV/OLV of $31.2M appears to significantly understate the liquid asset base and likely reflects a prior data vintage or model artifact; the current balance sheet shows materially higher liquid assets resulting from the July 2025 to April 2026 equity financing cycle that raised $1,069.1M net. The key risk to the liquidation posture is the operating lease stack in a soft San Francisco life sciences market, which at $83M face value is real exposure, and unresolved litigation where no reserve has been booked.